Studies reveal that ventricular tachycardia and ventricular fibrillation are responsible for the majority of cases of sudden cardiac death, accounting for 300,000 deaths annually in the United States. Ventricular tachycardia is also reported to have a strong association with coronary artery disease, with an estimated 15% of the patients affected by coronary artery disease having ventricular tachycardia. The rising burden of cardiovascular conditions is increasing the incidence of ventricular tachycardia, which is expected to fuel the demand for effective therapeutic interventions.
The Ventricular Tachycardia (V-tach or VT) Drug Pipeline Report by Expert Market Research gives comprehensive insights into ventricular tachycardia (V-tach or VT) drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ventricular tachycardia (V-tach or VT). The report includes the analysis of over 100 pipeline drugs and 50+ companies. The ventricular tachycardia (V-tach or VT) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from ventricular tachycardia (V-tach or VT).
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing ventricular tachycardia (V-tach or VT) pipeline development activities.
Ventricular tachycardia is defined as a fast, irregular heart rate that occurs in the lower chambers of the heart (ventricles), constituting three or more consecutive heartbeats at a rate of over 100 per minute. The condition is a potentially fatal arrhythmia and is responsible for a substantial percentage of sudden cardiac deaths in the United States. Ischemic heart disease is considered the most common cause of ventricular tachycardia.
Ventricular tachycardia (V-tach or VT) treatment is primarily focused on stabilizing the heart rhythm, preventing recurrence, and managing underlying causes. Antiarrhythmic drugs such as amiodarone, lidocaine, and procainamide are commonly used for preventing episodes of ventricular tachycardia. Advancements in understanding the electrical pathways of the heart are facilitating the identification of novel drug targets, which are likely to positively impact the ventricular tachycardia (V-tach or VT) pipeline landscape in the coming years.
This section of the report covers the analysis of ventricular tachycardia (V-tach or VT) drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
EMR’s ventricular tachycardia (V-tach or VT) therapeutic assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials for ventricular tachycardia (V-tach or VT).
The drug molecule categories covered under ventricular tachycardia (V-tach or VT) pipeline analysis include antisense oligonucleotides, gene therapy, hormones, neuropeptides, oligonucleotides, small molecules, and triglycerides. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ventricular tachycardia (V-tach or VT).
The EMR ventricular tachycardia (V-tach or VT) drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Ventricular Tachycardia (V-tach or VT) clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for ventricular tachycardia (V-tach or VT). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of ventricular tachycardia (V-tach or VT) drug candidates.
The objective of this multi-center, double-blind, placebo-controlled study is to assess the safety profile and efficacy of etripamil nasal spray (NS) self-administered by an estimated 500 patients who experience paroxysmal supraventricular tachycardia episodes in an at-home setting. The study is sponsored by Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. and is in Phase III clinical development.
Cardurion Pharmaceuticals, Inc. is conducting a Phase 2 study to investigate the pharmacokinetics, safety, tolerability, and pharmacodynamics of the ventricular tachycardia (V-tach or VT) drug candidate CRD-4730 in catecholaminergic polymorphic ventricular tachycardia (CPVT) patients. The study has enrolled around 12 participants and is expected to be completed by September 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Ventricular Tachycardia (V-tach or VT) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for ventricular tachycardia (V-tach or VT). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ventricular tachycardia (V-tach or VT) collaborations, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share